Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 8/20 | 0.52 |
| ▸ | PPARG | P37231 | 6/20 | 0.52 |
| ▸ | LPL | P06858 | 2/20 | 0.46 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.46 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.45 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20160762 | 0.89 | PPARA (0.50) | PPARAPPARGLPLLIPGCYP4F2 | |
| SCHEMBL29990726 | 0.87 | CYP4A11 (0.52) | PPARAPPARGCYP4F2CYP4A11HDAC1 | |
| SCHEMBL24172576 | 0.87 | CYP4A11 (0.52) | PPARAPPARGCYP4F2CYP4A11HDAC1 | |
| SCHEMBL29990524 | 0.86 | CNR1 (0.43) | PPARAPPARGCYP4F2CYP4A11HDAC1 | |
| SCHEMBL24172580 | 0.86 | CNR1 (0.43) | PPARAPPARGCYP4F2CYP4A11HDAC1 | |
| SCHEMBL19542672 | 0.84 | PPARA (0.52) | PPARAPPARGLPLLIPGHDAC1 | |
| SCHEMBL289829 | 0.84 | PPARA (0.59) | PPARAPPARGLPLLIPGCYP4F2 | |
| SCHEMBL289200 | 0.82 | PPARA (0.53) | PPARAPPARGLPLLIPGHDAC1 | |
| SCHEMBL24515429 | 0.80 | CNR1 (0.43) | CYP4F2CYP4A11 | |
| SCHEMBL14232380 | 0.80 | LOXL2 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210002202-A1 | Substituted Aromatic Compounds and Pharmaceutical Uses Thereof | PROMETIC BIOSCIENCES, INC. (CA) | 2021-01-07 | — | — | US | disclosed |
| US-20210002202-A1 | Substituted Aromatic Compounds and Pharmaceutical Uses Thereof | PROMETIC BIOSCIENCES, INC. (CA) | 2021-01-07 | — | — | US | disclosed |
| US-10815183-B2 | Substituted aromatic compounds and pharmaceutical uses thereof | PROMETIC PHARMA SMT LIMITED (GB) | 2020-10-27 | — | — | US | disclosed |
| US-10815183-B2 | Substituted aromatic compounds and pharmaceutical uses thereof | PROMETIC PHARMA SMT LIMITED (GB) | 2020-10-27 | — | — | US | disclosed |
| CN-105143170-B | For treating the aromatic compounds of pulmonary fibrosis, liver fibrosis, fibrosis of skin and cardiac fibrosis being substituted | 普罗米蒂克医药SMT有限公司 | 2019-11-08 | — | — | CN | disclosed |
| US-10450258-B2 | Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis | PROMETIC PHARMA SMT LIMITED (GB) | 2019-10-22 | — | — | US | disclosed |
| US-10450258-B2 | Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis | PROMETIC PHARMA SMT LIMITED (GB) | 2019-10-22 | — | — | US | disclosed |
| US-20180162799-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | PROMETIC PHARMA SMT LIMITED (GB) | 2018-06-14 | — | — | US | disclosed |
| US-20180162799-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | PROMETIC PHARMA SMT LIMITED (GB) | 2018-06-14 | — | — | US | disclosed |
| US-20180162799-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | PROMETIC PHARMA SMT LIMITED (GB) | 2018-06-14 | — | — | US | disclosed |
| US-8927765-B2 | Substituted aromatic compounds and pharmaceutical uses thereof | PROMETIC BIOSCIENCES INC. (CA) | 2015-01-06 | — | — | US | disclosed |
| US-8927765-B2 | Substituted aromatic compounds and pharmaceutical uses thereof | PROMETIC BIOSCIENCES INC. (CA) | 2015-01-06 | — | — | US | disclosed |
| WO-2014138907-A1 | SUBSTITUTED AROMATIC COMPOUNDS FOR THE TREATMENT OF PULMONARY FIBROSIS, LIVER FIBROSIS, SKIN FIBROSIS AND CARDIAC FIBROSIS | PROMETIC BIOSCIENCES INC. (CA) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014138907-A1 | SUBSTITUTED AROMATIC COMPOUNDS FOR THE TREATMENT OF PULMONARY FIBROSIS, LIVER FIBROSIS, SKIN FIBROSIS AND CARDIAC FIBROSIS | PROMETIC BIOSCIENCES INC. (CA) | 2014-09-18 | — | — | WO | disclosed |
| US-20120088784-A1 | Substituted Aromatic Compounds and Pharmaceutical Uses thereof | PROMETIC PHARMA SMT LIMITED (GB) | 2012-04-12 | — | — | US | disclosed |
| US-20120088784-A1 | Substituted Aromatic Compounds and Pharmaceutical Uses thereof | PROMETIC PHARMA SMT LIMITED (GB) | 2012-04-12 | — | — | US | disclosed |
| US-20120088784-A1 | Substituted Aromatic Compounds and Pharmaceutical Uses thereof | PROMETIC PHARMA SMT LIMITED (GB) | 2012-04-12 | — | — | US | disclosed |
| EP-2427416-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | ProMetic BioSciences Inc. (CA) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010127440-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | PROMETIC BIOSCIENCES INC. (CA) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010127440-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | PROMETIC BIOSCIENCES INC. (CA) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162799-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | TYR, PAH, REN | PPARA 276/4885PPARG 212/4885LPL 3442/4885 |
| US-10815183-B2 | Substituted aromatic compounds and pharmaceutical uses thereof | TYR, PAH, REN | PPARA 276/4885PPARG 212/4885LPL 3442/4885 |
| US-20210002202-A1 | Substituted Aromatic Compounds and Pharmaceutical Uses Thereof | TYR, PAH, REN | PPARA 276/4885PPARG 212/4885LPL 3442/4885 |
| US-10450258-B2 | Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis | PAH, HRH3, CFH | PPARA 3243/4885PPARG 2346/4885LPL 3753/4885 |
| US-20120088784-A1 | Substituted Aromatic Compounds and Pharmaceutical Uses thereof | TYR, PAH, REN | PPARA 276/4885PPARG 212/4885LPL 3442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.